Compositions of Matter
Acetylated, amidated short peptide bioregulators (Ac-X-NH2 dual-terminus modification) covering multiple Khavinson-lineage parent sequences across pineal, vascular, thymic, hepatic, pancreatic, and other tissue-specific axes.
Research · Intellectual Property
Patent Portfolio Overview
Provisional U.S. patent portfolio filed March 2026, anchoring the proprietary technology that enables modern endogenic practice.
Filing Summary
Eleven provisional applications. Four hundred eighty-eight claims.
Eleven provisional U.S. patent applications were filed on March 7, 2026, covering proprietary compositions, methods of use, and formulations across multiple indication areas. The portfolio comprises 488 claims and establishes a March 7, 2026 priority date. Non-provisional filings are due by March 7, 2027.
The portfolio anchors endogenic pharmacology's proprietary technology — specifically, the Ac-X-NH2 dual-terminus modification that enables non-injectable bioregulator delivery — and provides the institutional intellectual-property foundation for the commercial translation of the discipline.
Coverage Areas
Four claim categories.
Methods of Use
Therapeutic methods covering indication-specific applications across neurological, immune, vascular, longevity, and metabolic indication areas. Method claims address dosing schedules, route of administration, and indication-specific protocols.
Formulations
Pharmaceutical formulations enabling non-injectable bioregulator delivery — topical creams and serums, transdermal patches, intranasal sprays, sublingual troches and films, and oral preparations. Formulation claims cover stability, bioavailability, and delivery-route-specific compositions.
Combinations
Combination therapeutics pairing bioregulator compounds with co-administered agents — including delivery enhancers, stability adjuvants, and indication-aligned secondary actives — across the OTC opticeutical and Rx endoceutical tiers.
Inventorship and Assignment
Inventors of record.
The provisional applications name Daniel William Dorsey and Daniel Nowak as co-inventors. Assignment is held by the founding institutional entity. Licensing inquiries from qualified pharmaceutical, clinical, and research counterparties are directed through the institutional Contact pathway.